All articles tagged with #astrazeneca
Bristol Myers Squibb stock rose about 4% premarket after a Financial Times report that BMS and AstraZeneca discussed a potential $400 billion merger, while AstraZeneca ADRs fell. The deal would be one of the largest in pharma history and comes as 2026 sees a wave of big M&A activity, though analysts warned mega-deals can slow R&D productivity and pipeline progress.
Reuters reports AstraZeneca and Bristol Myers Squibb held preliminary talks about a potential merger valued at about $400 billion, which would create one of the world’s largest pharma companies. The status of talks is unclear, and such a deal would face U.S. antitrust scrutiny under the Trump administration and could require divestitures. The companies’ oncology franchises are a focal point, with historical context from Bristol Myers’ Celgene deal cited in analysis.
AstraZeneca and Bristol-Myers Squibb are reportedly in talks to merge, with a combined value near $400 billion that would create one of the world's largest pharma groups; no deal terms have been disclosed and talks could stall. Such a cross-border deal would face antitrust reviews in the US, UK, and EU, with investors awaiting more detail ahead of the Q3 2026 results in late October.
UK drugmaker AstraZeneca and US rival Bristol Myers Squibb are reportedly weighing a merger valued at about $400 billion, potentially the largest deal in history. Talks have been ongoing for months with no commitment or comment from either side, and the deal would reshape both companies’ cancer-drug portfolios and strategic positioning in the pharma industry.
AstraZeneca is in talks with Bristol Myers Squibb about a potential tie-up valued at roughly $400 billion, which would create one of the world's largest drugmakers. Discussions have been ongoing and could materialize soon but may also be delayed or collapse. The deal would reinforce AstraZeneca's US-focused pivot after its NY listing, with both companies keeping comments to themselves as talks proceed.
Earnings season kicks into high gear this week, with AstraZeneca reporting on Monday as a slate of results from SK Hynix, Visa, Coca-Cola, Boeing, Ford, ExxonMobil and Chevron follow later. The focus then shifts to Big Tech on Wednesday and Thursday, with Microsoft, Meta Platforms, Apple and Amazon.com set to report after Alphabet and Tesla, helping lift the market mood. Analysts project Q2 S&P 500 earnings growth around 23.2% year over year, well above the long‑term averages, indicating continued double‑digit earnings growth for the index.
AstraZeneca and Ionis reported that their heart-disease drug Wainua failed to outperform placebo in a pivotal trial for ATTR-CM (transthyretin-mediated amyloid cardiomyopathy), not reducing cardiovascular death or clinical events, and the news pushed both companies' shares down in premarket trading.
The FDA postponed its decision on AstraZeneca’s oral breast cancer drug camizestrant after an advisory committee voted (6-3) that the treatment did not show a clinically meaningful benefit in the Serena-6 switching trial. AstraZeneca provided additional analyses requested by the agency, including circulating tumor DNA data, and the FDA is reviewing them before issuing a ruling; no new decision date has been set. Europe has given a positive opinion for camizestrant, which will be marketed as Etcamah there.
An FDA advisory panel voted 6-3 against approving AstraZeneca's oral breast cancer drug camizestrant due to concerns about trial design, sending AstraZeneca shares about 2% lower in London. While the panel did not question the drug's safety, it said the SERENA-6 results did not prove that early switching to camizestrant improves long-term survival. The company will continue working with the FDA as it reviews the application, and analysts say the setback may be more sentiment-related than a fundamental issue for the stock.
An FDA advisory panel voted 6-3 against approving AstraZeneca's oral SERD camizestrant for HR-positive, HER2-negative metastatic breast cancer with ESR1 mutations detected before progression, citing insufficient evidence of a meaningful long-term benefit and trial-design concerns (no crossover, OS data immature). Approval now seems unlikely despite a progression-free survival improvement seen in Serena-6.
The FDA will speed drug development by reviewing real-time trial data from AstraZeneca and Amgen and is seeking public input on a pilot using AI to improve safety monitoring, dosing, and recruitment. The efforts include AZ’s Phase 2 lymphoma trial at MD Anderson and UPenn, and Amgen’s Phase 1b small cell lung cancer study, all supported by Paradigm Health’s real-time data platform.
The FDA announced a pilot to let reviewers access safety and efficacy signals from ongoing clinical trials in real time via a cloud platform, with AstraZeneca and Amgen participating, aiming to cut development time and speed regulatory decisions without replacing traditional sponsor meetings. A parallel AI pilot to optimize early trials is planned, and public comments are invited, all while safeguarding patient privacy.
AstraZeneca's anti-IL-33 antibody tozorakimab posted positive Phase 3 results in COPD (Oberon and Titania), reducing the annualized rate of moderate-to-severe exacerbations versus placebo in former smokers and showing benefit across the overall population, with a favorable safety profile. The drug’s supposed differentiation comes from complete inhibition of ST2 and RAGE/EGFR signaling, unlike rivals Roche and Sanofi/Regeneron’s IL-33 blockers that produced mixed results. AZ plans to present full data at an upcoming meeting and is pursuing two additional Phase 3 trials (Prospero, Miranda), while maintaining a target of potentially $3–5 billion in peak sales if approved.
AstraZeneca will pay up to $630 million to acquire the remaining China rights to its GPC3-targeting CAR-T therapy C-CAR031, giving it full global rights; the deal follows a prior China arrangement and aligns with AZ's push to develop CAR-T therapies for hepatocellular carcinoma, which showed promising early responses in China.
The FDA has approved AstraZeneca and Daiichi Sankyo's drug Enhertu, in combination with Roche's Perjeta, as a first-line treatment for advanced HER2-positive breast cancer, based on a study showing improved progression-free survival and tumor response.